Overview
- Sofinnova Partners finalized Sofinnova Capital XI at €650 million ($750 million), exceeding its initial target.
- Most capital is earmarked for biotechnology drug developers, with 20% to 30% allocated to medical device companies.
- The fund is participating in both initial financings and follow-on rounds across core U.S. and European markets.
- Deployment has begun with investments in several companies, including Actithera and Elevara Medicines.
- A diverse, largely returning limited partner base from Europe, North America, Asia and the Middle East committed, as peers like Medicxi, Deerfield, Omega and Atlas also closed new funds following a Q3 pickup identified by William Blair.